YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Sobi plans to publish its report for the third quarter of 2026 on 27 October 2026 at 08:00 CET. STOCKHOLM, Oct. 8, 2026 /PRNewswire/ -- Investors, analysts, and the media are invited to a conference call on the same day at 15:00 CET, 14:00…
STOCKHOLM, Sept. 30, 2026 /PRNewswire/ -- As per 30 September 2026, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 357,636,514 shares. All shares are common shares. The total number of votes is 357,636,…
STOCKHOLM, Sept. 24, 2026 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that new clinical data on Gamifant® (emapalumab) in primary haemophagocytic lymphohistiocytosis (HLH) will be presented at the 2026 Annual Meeting of the Histiocyt…
Aytu BioPharma, Inc. (AYTU) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.26 per share a year ago. These figures are adjusted for non-recurring items…
STOCKHOLM, Sept. 16, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that the previously announced strategic partnership…
Sobi, Inc. WALTHAM, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the US Food and Drug Administration (FDA) has granted Fast Track de…
STOCKHOLM, Aug. 31, 2026 /PRNewswire/ -- The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 6 May 2026 resolved on a directed issue of redeemable and convertible class C shares and to authorise the Board of Directo…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why Swedish Orphan Biovitrum Stock Is Back In Focus Swedish Orphan Biovitrum (OM:SOBI) has drawn fresh attention after…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Swedish Orphan Biovitrum has delivered a strong share price run over the past five years, yet its…
STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to ena…
MARSEILLE, France, August 10, 2026--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") and Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced that they have entered a…
BioNTech SE Mainz, Germany, August 3, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") announced today that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Management Board as Chief Executive…
STOCKHOLM, Aug. 3, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announces that Guido Oelkers has informed the Board of Directors that he has decided to step down as Chief Executive Officer of Sobi to take up anothe…
This article first appeared on GuruFocus. Revenue Growth: 29% at constant exchange rates. Adjusted EBITDA Margin: 35% for Q2. Total Net Sales: Just under SEK7.8 billion for the quarter. Geographic Revenue Growth: North America 33%, Interna…
STOCKHOLM, July 16, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter of 2026. Second Quarter 2026 Total revenue increased 29 per cent at CER (constant exchange rates), 27 per…
STOCKHOLM, July 15, 2026 /PRNewswire/ -- The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 6 May 2026, resolved - for the purpose of ensuring that the company can fulfil its commitments under the long-term incenti…
Sobi, Inc. This recommendation represents an important step towards improving access for Canadians living with rare kidney diseases WALTHAM, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) is…
STOCKHOLM, July 1, 2026 /PRNewswire/ -- Sobi plans to publish its report for the second quarter of 2026 on 16 July 2026 at 08:00 CEST. Investors, analysts, and the media are invited to a conference call on the same day at 14:00 CEST, 13:00…
New analyses and real-world evidence highlight outcomes with Altuvoct®, Elocta® and Alprolix® in haemophilia A and B STOCKHOLM, June 30, 2026 /PRNewswire/ -- Sobi® today announced new data across its haemophilia portfolio will be presented…
STOCKHOLM, June 26, 2026 /PRNewswire/ --The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical safety or efficacy concerns were identified that impac…
Sobi's presentations highlight research across multiple rare diseases in haematology including PNH, ITP, HLH and myelofibrosis. STOCKHOLM, June 11, 2026 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that new clinical and real-world dat…
Swedish Orphan Biovitrum recently reported Phase 3 data showing that Tryngolza (olezarsen) and pozdeutinurad both met key efficacy and safety goals in severe hypertriglyceridemia and gout, respectively. The olezarsen analysis in patients w…
STOCKHOLM, June 1, 2026 /PRNewswire/ -- Sobi® today announced that new data from the pegcetacoplan clinical development programme and related research in C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonep…
STOCKHOLM, May 26, 2026 /PRNewswire/ -- Sobi® (STO: SOBI) today announced results from a new analysis of the pivotal Phase 3 CORE and CORE2 trials, showing Tryngolza® (olezarsen) reduced the relative risk of acute pancreatitis events by 85…
Enable Injections, Inc. Regulatory milestone expands access to wearable, patient-centric drug delivery for rare disease treatment across Europe CINCINNATI, May 22, 2026 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare i…
Both doses of once-daily pozdeutinurad (AR882) met the primary efficacy endpoint of sUA reduction at month 6 vs placebo Pozdeutinurad was overall well tolerated, and the safety profile was consistent with previous studies STOCKHOLM, May 21…
STOCKHOLM, May 6, 2026 /PRNewswire/ -- The Swedish Orphan Biovitrum AB (publ) (Sobi®) AGM was convened today on 6 May 2026. At the AGM, the shareholders, in accordance with the proposed resolutions, resolved as follows: Adoption of the pro…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Recent share performance and what it means for investors Swedish Orphan Biovitrum (OM:SOBI) has drawn investor attentio…
Company Logo Key market opportunities for Altuviiio include the demand for long-acting therapies, expanded prophylaxis guidelines, and increased pediatric treatment uptake. The shift towards extended half-life therapies and enhanced patien…
This article first appeared on GuruFocus. Revenue Growth: 24% at constant exchange rate. Adjusted EBITA Margin: 38%. Strategic Portfolio Growth: 55%, contributing 63% of total business. Altuvoct Revenue Growth: 186%. Gamifant Sales: SEK734…
STOCKHOLM, April 28, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter of 2026. First Quarter 2026 Total revenue increased 24 per cent at CER (constant exchange rates), 11 per…
(RTTNews) - Swedish Orphan Biovitrum AB (publ) (SWOBYI, BIOVF, SOBI.ST), a biopharmaceutical company, announced that Health Canada has approved EMPAVELI or Pegcetacoplan for the treatment of adult and pediatric patients aged 12 years and o…
Sobi, Inc. EMPAVELI®(pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced proteinuria, stabilized kidne…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. European Medicines Agency validates Swedish Orphan Biovitrum’s application to extend the indication of Tryngolza (oleza…
STOCKHOLM, March 31, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today published its Annual and Sustainability report for 2025, outlining the company's progress in unlocking the potential of breakthrough innovations and…
STOCKHOLM, March 27, 2026 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be held on Wednesday, 6 May 2026 at 10.00…